Perspectives on Triple-Negative Breast Cancer

Slides:



Advertisements
Similar presentations
World Cancer Day 2017 We Can, I Can Do you know this?
Advertisements

Triple-Negative and BRCA-Mutated Metastatic Breast Cancer
Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer 
Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Evolving Paradigms in Recurrent/Metastatic SCCHN
The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.
The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.
Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.
Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
Her2-positive breast cancer: updating current best practice
Assessing the Impact: New Data in T790+ NSCLC
Updates in Hodgkin Lymphoma
Does One Size Fit All in Obesity Management?
Progression After Cancer Immunotherapy in Advanced NSCLC
سرطان الثدي Breast Cancer
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Neoadjuvant Therapy in HER2-Positive Breast Cancer
Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Tailoring Hemophilia Prophylaxis Therapy
Managing gBRCA-Positive Metastatic Breast Cancer
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
From Symptom Management to Communication in Advanced GI Cancers
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Optimizing Neoadjuvant Treatment for Primary Breast Cancer
Program Goals Disclaimer Overview Assessing Disease Activity.
Charting Progress in MS Treatment:
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
When Is Biologic Therapy Appropriate for HS?
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Best Practices in Lymph Node Mapping and Localization: Melanoma
Evolving Concepts in the Management of Head and Neck Cancers
Staying Abreast of Best Practices Across the Clinical Continuum
The Road to Quality Improvement in HER2-Positive Breast Cancer
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
What's New in PAH?.
Management of Advanced Pancreatic Adenocarcinoma
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
All for One: Multidisciplinary Management in EGFR-Mutated NSCLC
Practical Guidance on the Management of Pan-Negative NSCLC
A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.
Incorporating Prostacyclins Into Practice
Preparing for Checkpoint Inhibitors in Breast Cancer
Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).
Improving Adherence to Antiplatelet Therapy After an ACS Event
An inflammatory triple negative breast cancer of an African woman before (A) and after (B) treatment. An inflammatory triple negative breast cancer of.
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
Breast Multidisciplinary Team Meetings
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Evaluating the Totality of Evidence
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
Clinical Focus.
The Nurse View.
Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.
Heterogeneity in the natural history of triple negative breast cancer.
Genomic determinants of response to cytotoxic chemotherapy.
Uncovering the Right Sequence
Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.
Presentation transcript:

Perspectives on Triple-Negative Breast Cancer

Learning Objectives

Patient Case: Newly Diagnosed TNBC

Platinum Agents in Treatment of TNBC

Platinum Experience in TNBC: Neoadjuvant Setting

Who Benefits?

Patient Case: BH (cont)

Patient Case: BH (cont)

Treatment of Metastatic Disease

Treatment of Metastatic Disease: General Principles

Other Cytotoxic Options for TNBC Chemotherapy

tnAcity: Study Design (NCT01881230)

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)